论文部分内容阅读
目的探讨紫杉醇加顺铂联合同步放疗治疗中晚期食管癌的治疗效果。方法 60例中晚期食管癌患者,将其随机分成观察组和对照组两组,每组各30例,其中观察组患者采用紫杉醇加顺铂联合同步放疗的治疗方法,而对照组采用单纯放疗的治疗方法;观察记录并比较两组患者的近期治疗效果、1年生存率、局部控制率和远处转移率以及不良反应发生率。结果观察组和对照组相比较,观察组总有效率90%、1年生存率86.67%和局部控制率70.00%,均高于对照组,但是观察组1年的远处转移率10.00%明显低于对照组的30%,差异有统计学意义(P<0.05)。结论针对中晚期食管癌患者,采用紫杉醇加顺铂联合同步放疗治疗的方法,效果显著,能够有效地提高患者的生存率,同时能够很好地改善患者预后的质量,具有较好的临床推广意义。
Objective To investigate the efficacy of paclitaxel plus cisplatin combined with concurrent radiotherapy in the treatment of advanced esophageal cancer. Methods Sixty patients with advanced esophageal cancer were randomly divided into observation group and control group, with 30 cases in each group. Patients in observation group were treated with paclitaxel plus cisplatin combined with concurrent radiotherapy, while those in control group were treated with radiotherapy alone Treatment; observed and recorded and compared the two groups of patients with short-term treatment, 1-year survival rate, local control and distant metastasis rate and the incidence of adverse reactions. Results Compared with the control group, the total effective rate in the observation group was 90%, the 1-year survival rate was 86.67% and the local control rate was 70.00%, which were significantly higher in the observation group than those in the control group. However, the distant metastasis rate in the observation group at 1 year was significantly lower at 10.00% 30% of the control group, the difference was statistically significant (P <0.05). Conclusion For patients with advanced esophageal cancer, the combination of paclitaxel and cisplatin combined with concurrent radiotherapy has a significant effect, which can effectively improve the survival rate of patients, and can improve the prognosis of patients with good quality, and has good clinical significance .